FIELD: medicine.
SUBSTANCE: invention relates to method of obtaining gemcitabine hydrochloride, characterised by the following: 2,2-dimethyl-[1,3]-dioxolane-4-carbaldehyde is subjected to interaction with ethyl bromodifluoracetate in presence of zinc in organic solvent medium processing reaction mixture with ultrasound for 5-60 minutes, obtained ethyl 3-hydroxy-2,2-difluoro-3-[2,2-dimethyl-[1,3]dioxolane-4-yl]propionate is subjected to hydrolysis and cyclisation by means of ion-exchange resin in water-alcohol medium obtaining (4R,5R)-4-hydroxy-5-hydroxymethyl-3,3-difluorodihydrofuran-2(3H)-on, which is processed with solution of trimethylchlorosilane in dichloromethane obtaining (4R,5R)-4-trimethylsilyloxy-5-((trimethylsilyloxy)methyl)-3,3-difluorodihydrofuran-2(3H)-on, which is subjected to reduction by means of lithium diisopropylalumohydride in organic solvent medium at cooling to -70°C obtaining (4R,5R)-2-hydroxy-4-(trimethylsilyloxy)-5-((thrimethylsilyloxy)methyl)-3,3-difluorotetrahydrofurane, which is converted into (4R,5R)-2-methylsulphonyloxy-4-(trimethylsilyloxy)-5-((trimethylsilyloxy)methyl)-3,3-difluorotetrahydrofurane by processing with methane sulphonylchloride in solvent medium at cold, obtained (4R,5R)-2-methylsulphonyloxy-4-(trimethylsilyloxy)-5-((trimethylsilyloxy)methyl)-3,3- difluorotetrahydrofurane after optic isomer separation is processed with bis-trimethylsilylacetylcytozine in water-free dichlorethane and boil with trifluoromethane sulphonyloxymethylsilane with further cooling and separation of obtained gemcitabine in form of base or hydrochloride, as well as method of gemcitabine hydrochloride purification by its re-crystallisation from water solution with processing with ultrasound.
EFFECT: invention results in increase of ratio 3-(R)-hydroxy-isomer to 3(S)-hydroxy-isomer.
6 cl, 2 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED (2R,3R,5R)-3-HYDROXY-(5-PYRIMIDIN-1-YL)TETRAHYDROFURAN-2-YLMETHYL ARYL PHOSPHORAMIDATES | 2013 |
|
RU2553996C1 |
MACROHETEROCYCLIC NUCLEOSIDE DERIVATIVES AND ANALOGUES THEREOF, PRODUCTION AND USE | 2017 |
|
RU2731385C1 |
COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
N-DIHYDROALKYLSUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVES | 2006 |
|
RU2414456C2 |
METHOD OF PRODUCING RIBOFURANOSYL-PYRIMIDINE NUCLEOSIDES | 2007 |
|
RU2421461C2 |
METHOD FOR OBTAINING FLUOROLACTONE DERIVATIVE | 2014 |
|
RU2656600C2 |
C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | 2011 |
|
RU2606501C2 |
HYPOGLYCAEMIC MEDICINAL AGENT COMPRISING POLYHYDROXYBUTYLPYRAZINES, NEW POLYHYDROXY-BUTYLPYRAZINES AND METHODS OF THEIR SYNTHESIS | 1998 |
|
RU2186773C2 |
COMPOUNDS - SULFAMATE DERIVATIVES FOR USE IN TREATING OR RELIEVING PAIN | 2014 |
|
RU2699025C1 |
AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR | 2017 |
|
RU2764523C2 |
Authors
Dates
2009-05-20—Published
2007-07-11—Filed